ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
IPO Year: 2014
Exchange: NASDAQ
Website: proqr.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2026 | $9.00 | Outperform | Oppenheimer |
| 4/29/2025 | $5.00 | Outperform | Evercore ISI |
| 4/29/2025 | $8.00 | Overweight | Cantor Fitzgerald |
| 3/10/2025 | $4.00 | Neutral → Buy | Citigroup |
| 1/10/2025 | $15.00 | Outperform | Oppenheimer |
| 10/29/2024 | $6.00 → $14.00 | Outperform → Strong Buy | Raymond James |
| 11/8/2023 | $2.00 | Neutral → Buy | Chardan Capital Markets |
| 3/30/2023 | $1.50 → $5.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 12/22/2022 | $0.80 → $5.00 | Neutral → Overweight | Cantor Fitzgerald |
| 2/14/2022 | $18.00 → $8.00 | Buy | Chardan Capital |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
20-F - ProQR Therapeutics N.V. (0001612940) (Filer)
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Oppenheimer resumed coverage of ProQR Therapeutics with a rating of Outperform and set a new price target of $9.00
Evercore ISI initiated coverage of ProQR Therapeutics with a rating of Outperform and set a new price target of $5.00
Cantor Fitzgerald resumed coverage of ProQR Therapeutics with a rating of Overweight and set a new price target of $8.00
Citigroup upgraded ProQR Therapeutics from Neutral to Buy and set a new price target of $4.00
Oppenheimer initiated coverage of ProQR Therapeutics with a rating of Outperform and set a new price target of $15.00
Raymond James upgraded ProQR Therapeutics from Outperform to Strong Buy and set a new price target of $14.00 from $6.00 previously
Chardan Capital Markets upgraded ProQR Therapeutics from Neutral to Buy and set a new price target of $2.00
JMP Securities upgraded ProQR Therapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00 from $1.50 previously
Cantor Fitzgerald upgraded ProQR Therapeutics from Neutral to Overweight and set a new price target of $5.00 from $0.80 previously
Chardan Capital reiterated coverage of ProQR Therapeutics with a rating of Buy and set a new price target of $8.00 from $18.00 previously
Fastest customizable press release news feed in the world
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indicationPipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalystsContinued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory BoardEnded Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives throu
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced presentations at several upcoming scientific conferences, highlighting continued progress in the application of its Axiomer RNA editing platform. "These presentations collectively expand the body of evidence supporting the potential of our Axiomer RNA editing platform to enable precise RNA editing across multiple targets," said Gerard Platenburg, Co-founder and Chief Scientific Officer of ProQR. "Acro
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Tuesday, June 2, 2026 at 1500 CEST at the offices of Allen Overy Shearman Sterling LLP, in Amsterdam, the Netherlands. All relevant documents and information for the meeting, including the notice and agenda and explanatory notes, are or will be made available in the "Investors & Media" section of ProQR's website (www.proqr.com) under
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, to its Board of Directors. "We are pleased to nominate Lykke to our Board of Directors," said James Shannon, MD, Chairperson of the Board of ProQR Therapeutics. "Her extensive experience in global drug development and broad perspective across therapeutic areas will complement t
AX-0810 clinical target engagement data in healthy volunteers on track for this quarter; biliary atresia selected as initial Phase 2 indicationAdditional programs advancing toward the clinic, including AX-0811 and AX-0422Axiomer platform supporting multiple additional clinical data readouts within current runway LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key updates from its virtual Investor and Analyst event hosted today. During the event, ProQR prov
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR's AI-enabled drug discovery for Axiomer™ProQR establishes AI Advisory Board with leaders from industry and academiaProQR's first AI-discovered Development Candidate expected to enter the clinic in 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced its AI strategy to enhance discovery on the Axiomer platform, including a partnership with Ginkgo Bioworks
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will host a virtual Investor and Analyst Event highlighting its pipeline entitled: "Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810" Ahead of the anticipated target engagement data for AX-0810 in the first half of 2026, the Company will showcase ProQR's broader RNA editing pipeline at this event, announce new programs that will have clinical data readouts in the runway, and unveil the primar
Advancing AX-0810 through ongoing Phase 1 dosing, with target engagement data expected 1H 2026Selected Development Candidates AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Ended 2025 with € 92.4 million cash and cash equivalents and achieved $4.5 million in Eli Lilly collaboration milestones in 2025, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended Decem
Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital Shah appointed Chief Financial and Business Officer SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale of an additional $50 million of shares of its common stock to investors from its July 2025 equity private placement of up to $100 million, following achievement of a clinical milestone within its Pi
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will present at the Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 3:25pm ET. A live webcast and recording of this presentation will be available from the "Investors & Media" section of ProQR's website (www.proqr.com) under "Events". Archived webcasts will be available for approximately 30 days following the presentation date. About Axiomer™ ProQR is pione
Live Leadership Updates
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting (AGM) as their terms conclude. The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planni
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dennis Hom as Chief Financial Officer (CFO) and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer (CMO). These key leadership appointments support the advancement of the Company's Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage. "We are thrilled to welcome Dennis and Cristina to ProQR at such an important time in our evolution," said Daniel A
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR's Scientific Advisory Board, where he has played an important role in shaping the Company's ADAR-based RNA editing platform. Dr. Beal's decades of res
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined ProQR as a strategic advisor. "It is a great honor to have John engaged with ProQR as a strategic advisor to the Supervisory Board to support us in defining the next steps for the Company, while we continue to analyze data from the Illuminate trial of sepofarsen and identify next steps for the program, if any,"
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022Five-target collaboration with Lilly highlights significant potential of ProQR's Axiomer® RNA base-editing platform and strengthens financial position with $50 million in upfront and equity and up to $1.25 billion in milestonesQR-421a Phase 2/3 Sirius and Celeste trials in Usher syndrome and retinitis pigmentosa on track to start by year end 2021Company to host an "Analyst Event" on November 18, 2021 to highlight clinical stage pipeline programs and Axiomer® RNA editing platform LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ProQR The
Senior leader with extensive global rare disease commercialization experienceTop-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the appointment of Theresa Heggie as Chief Commercial Officer reporting to Daniel de Boer, Founder and CEO. In this newly created leadership position, Ms. Heggie will be responsible for overseeing the Company's commercial strategy and global comme
This live feed shows all institutional transactions in real time.
SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
SC 13G - ProQR Therapeutics N.V. (0001612940) (Subject)
SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
Live finance-specific insights
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team. During the event, ProQR will highlight its proprietary Axiomer™ ADAR-mediated RNA editing platform, along with updates on its pipeline of development candidates including data updates and next steps on its programs for NTCP and B4GALT1, AX-0810 and AX-1412. Prese
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company's AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual MeetingManagement webinar May 9, 2024 at 8:00 am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced new preclinical data for its proprietary Axiomer™ RNA editing technology platform, incl
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the Company's Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST. The live and archived webcast of the presentation will be accessible through this webcast link, or to access the live call by phone please register here. A dial-in and unique PIN will be provided to join the call. The
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023Additional pivotal trial recommended by EMA for sepofarsen prior to a regulatory submissionCompany will seek a strategic partner for ophthalmology assets Workforce reduction to be implemented within clinical stage ophthalmology programs Cash runway extended into 2026 Conference call today at 8:15am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (the "Company"), a company dedica
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators in Q3Illuminate results and post-hoc analyses to be presented at the upcoming Seventh Annual Retinal Cell and Gene Therapy Innovation Summit and the ARVO 2022 Annual MeetingCorporate strategy to focus on accelerating the development of Axiomer® RNA base-editing technology platform across multiple therapeutic areas; Company to continue development of select Inherited Retinal Disease (IRD) programs, subject to regulatory feedbackCompan
Study did not meet primary endpoint nor notable secondary endpoints – no benefit observed in either treatment arm versus shamAdditional analyses to be conducted and presented at a future medical congressSepofarsen continues to be generally well toleratedStrong cash position provides runway into mid- to late-2024ProQR Management to host conference call today at 8:15am EST LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced its pivotal Phase 2/3 Illuminate trial of sepofarsen for th
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that ProQR management will host an investor conference call and webcast to discuss the Company's Axiomer RNA editing technology platform following the recently announced partnership with Lilly. ProQR will host the call on September 9, 2021, at 8:15am EDT. The live and archived webcast of this presentation will be accessible through this webcast link or through the Events page of the Company's website. The dial-in details for the call are